DDInter1702 DDInter1435
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Sorafenib {u} (Compound) resembles {v} (Compound) Vismodegib
Sorafenib {u} (Compound) treats {v} (Disease) liver cancer
Sorafenib {u} (Compound) binds {v} (Gene) BRAF
Sorafenib {u} (Compound) upregulates {v} (Gene) TSC22D3
Sorafenib {u} (Compound) downregulates {v} (Gene) MCM3
Sorafenib {u} (Compound) causes {v} (Side Effect) Hepatobiliary disease
Sorafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trimipramine
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tacrine
Sorafenib {u} may lead to a major life threatening interaction when taken with {v} Ibutilide
Sorafenib (Compound) resembles Vismodegib (Compound)
Sorafenib (Compound) treats liver cancer (Disease)
Sorafenib (Compound) binds BRAF (Gene)
Sorafenib (Compound) upregulates TSC22D3 (Gene)
Sorafenib (Compound) downregulates MCM3 (Gene)
Sorafenib (Compound) causes Hepatobiliary disease (Side Effect)
Sorafenib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Tacrine
Sorafenib may lead to a major life threatening interaction when taken with Ibutilide